The polymorphism of IL18RAP and IL18R1 genes associated with risks of the development of myocardial infarction in patients with stable coronary artery disease

Objective:to assess the probability of pathogenic effects OF Il-18 (IL18, IL18R1 and IL18RAP) gene polymorphism on the risk of myocardial infarction in patients with stable coronary heart disease.Materials and methods: the present study was performed with the inclusion of 260 patients with stable coronary heart disease (CHD), residents of the industrial region of Western Siberia. Molecular genetic testing was performed on nine polymorphic sites of il18, IL18R1, IL18RAP genes.Results:associations of polymorphic sites rs13015714 IL18R1 and rs917997 IL18RAP with risks of myocardial infarction were Determined (OR =1.95 (95% CI =1.06-3.58), p =0.029 and OR =2.01 (95% CI =1.11-3.64), p=0.018).Conclusion:to confirm the role of polymorphism IL18, IL18R1, IL18RAP in the pathogenesis of atherosclerosis, prospective monitoring of this group of patients is necessary to identify cases of manifestation of clinical signs in persons with adverse prognosis.

Download Full-text

The role of markers of endothelial dysfunction, oxidative and cellular stress in the prediction of myocardial infarction in comorbid patients with stable coronary heart disease

Cardiosomatics ◽

10.26442/22217185.2021.1.200768 ◽

2021 ◽

Vol 12 (1) ◽

pp. 23-27

Author(s):

Yuliya A. Kotova ◽

Anna A. Zuikova ◽

Natalia V. Strahova ◽

Olga N. Krasnorutskaya ◽

Elena Y. Esina

Keyword(s):

Myocardial Infarction ◽

Coronary Heart Disease ◽

Heart Disease ◽

Endothelial Dysfunction ◽

Average Strength ◽

Stable Coronary Heart Disease ◽

History Of ◽

Modified Proteins ◽

Hs Crp

Aim. To study the role of markers of endothelial dysfunction, oxidative and cellular stress in the prediction of myocardial infarction (MI) in comorbid patients with stable coronary heart disease (CHD). Material and methods. The study involved 336 patients with a diagnosis of CHD. The presence of CHD was confirmed by diagnostic coronary angiography with the calculation of the Gensini index. All patients were divided into 2 groups: group 1288 patients without a history of MI, group 248 patients with a history of MI. All patients were assessed for the levels of oxidized modified proteins, high-sensitivity C-reactive protein (hs-CRP), homocysteine, heat shock protein (HSP70), and superoxide dismutase activity. Results. All patients were comparable in age. For other clinical and anthropometric characteristics, we saw significant differences (according to the MannWhitney criterion): patients with previous MI had higher BMI, waist circumference, and blood pressure. The correlation analysis revealed positive significant average strength relationships between past MI and the Gensini index, low-density lipoprotein level, total cholesterol level, homocysteine level, hs-CRP level, and the level of oxidized modified proteins; and negative significant average strength relationships between past MI and SOD activity level (r=-0.374, p=6.4 E-07) and HSP70 level (r=-0.563, p=2.6 E-15). The ROC analysis revealed that not all markers were significant in predicting the risk of MI. It is shown that the most expected characteristics were shown by the hs-СRP. However, further analysis of the predictive significance of the markers demonstrated that the addition of HSP70 to hs-CRP increases the predictive significance of hs-CRP in relation to the risk of developing MI. Conclusion. We have demonstrated that a strategy using a cumulative risk assessment consisting of 2 biomarkers (individually involved in inflammation and stress-induced cellular responses) can identify patients with an established diagnosis of CHD who have an increased risk of acute MI.

Download Full-text

LIFE QUALITY ASSESSMENT OF PATIENTS WITH STABLE CORONARY ARTERY DISEASE AFTER MYOCARDIAL REVASCULARIZATION

Pharmacy & Pharmacology ◽

10.19163/2307-9266-2020-8-6-465-475 ◽

2021 ◽

Vol 8 (6) ◽

pp. 465-475

Author(s):

I. A. Narkevich ◽

O. D. Nemyatykh ◽

K. A. Kovaleva ◽

L. G. Ratova ◽

I. O. Trushnikova ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Heart Disease ◽

Heart Disease ◽

Coronary Artery ◽

Coronary Arteries ◽

Stable Coronary Artery Disease ◽

Life Quality ◽

Stable Coronary Heart Disease ◽

Artery Disease ◽

Angioplasty And Stenting

The aim of this study is to assess the life quality of patients with stable coronary artery disease after angioplasty and stenting of coronary arteries at the post-hospital stage.Materials and methods. Methods of the sociological analysis (questionnaire surveys) and methods of mathematical statistics (descriptive statistics, time series method, factor and variance analyses) were used at different stages of the prospective observational study. The research materials were as follows:1458 electronic patient records with a stable coronary heart disease (SCHD) after angioplasty and stenting of coronary arteries (ASCA); 620 questionnaires filled in by patients before the surgery, 1, 6, 12 months after discharge. The statistical analysis was performed using the IBM SPSS Statistics software.Results. The results of a comprehensive survey make it possible for us to assert that during the studied period, stable good healths of cardiac surgery patients with ASCA were maintained. Within the framework of the EQ-5D-5L questionnaire, it was revealed that more than 50% of patients have no physiological problems. The results of the SAQ analysis demonstrate that 58% of the patients feel better, and more than 34% of the patients do not have shortness of breath 1 year after the surgery. A statistically significant improvement in their healths was established according to a visual analogue scale relatively to the annual observation mark (62.82 ± 20.95), which corresponds to the high results assessment of the medical technology use. At the same time, 53% of the patients notify that the treatment results meet their own expectations.Conclusion. The proposed calculation of the integrated index of patients’ treatment efficiency demonstrated by the patients with stable coronary heart disease after angioplasty and stenting of the coronary arteries is based on the results of the factor analysis. This calculation can be used to assess the efficiency of pharmacotherapy in the framework of a value-oriented approach to the treatment of a number of other pathologies.

Download Full-text

No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study

European Journal of Preventive Cardiology ◽

10.1177/2047487319894679 ◽

2019 ◽

pp. 204748731989467 ◽

Cited By ~ 3

Author(s):

Liu Miao ◽

Guo-Xiong Deng ◽

Rui-Xing Yin ◽

Rong-Jun Nie ◽

Shuo Yang ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Coronary Heart Disease ◽

Heart Disease ◽

Mendelian Randomization ◽

Plasma Homocysteine ◽

Sensitivity Analyses ◽

Nucleotide Polymorphisms ◽

Genome Wide ◽

Artery Disease

Background Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. In this study, we estimated the role of increased plasma homocysteine levels on the etiology of coronary heart disease and acute myocardial infarction. Methods A two-sample Mendelian randomization study on disease was conducted, i.e. “coronary heart disease” ( n = 184,305) and “acute myocardial infarction” ( n = 181,875). Nine single nucleotide polymorphisms, which were genome-wide significantly associated with plasma homocysteine levels in 57,644 subjects from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics (CARDIoGRAMplusC4D) consortium genome-wide association study and were known to be associated at p < 5×10–8, were used as an instrumental variable. Results None of the nine single nucleotide polymorphisms were associated with coronary heart disease or acute myocardial infarction ( p > 0.05 for all). Mendelian randomization analysis revealed no causal effects of plasma homocysteine levels, either on coronary heart disease (inverse variance weighted; odds ratio = 1.015, 95% confidence interval = 0.923–1.106, p = 0.752) or on acute myocardial infarction (inverse variance weighted; odds ratio = 1.037, 95% confidence interval = 0.932–1.142, p = 0.499). The results were consistent in sensitivity analyses using the weighted median and Mendelian randomization-Egger methods, and no directional pleiotropy ( p = 0.213 for coronary heart disease and p = 0.343 for acute myocardial infarction) was observed. Sensitivity analyses confirmed that plasma homocysteine levels were not significantly associated with coronary heart disease or acute myocardial infarction. Conclusions The findings from this Mendelian randomization study indicate no causal relationship between plasma homocysteine levels and coronary heart disease or acute myocardial infarction. Conflicting findings from observational studies might have resulted from residual confounding or reverse causation.

Download Full-text

Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels

Circulation ◽

10.1161/circ.142.suppl_3.13769 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Narek A Tmoyan ◽

Marat V Ezhov ◽

Olga I Afanasieva ◽

Uliana V Chubykina ◽

Elena A Klesareva ◽

...

Keyword(s):

Myocardial Infarction ◽

Coronary Heart Disease ◽

Heart Disease ◽

Cardiovascular Diseases ◽

Carotid Artery ◽

Lower Extremity ◽

Carotid Artery Disease ◽

Lipoprotein A ◽

Artery Disease ◽

Lower Extremity Artery Disease

Introduction: There is no common opinion about threshold lipoprotein(a) [Lp(a)] concentration for atherosclerotic cardiovascular diseases (ASCVD) risk. Different clinical guidelines and consensus documents postulated cut-off Lp(a) level as 30 mg/dL or 50 mg/dL. We assessed the concentration of Lp(a) that associated with ASCVD of different locations. Methods: The study included 1224 patients with ASCVD. Lp(a) concentration was measured by enzyme-linked immunosorbent assay in serum. Patients were divided into 3 groups: group I - Lp(a)<30 mg/dL, group II - 30≤Lp(a)<50 mg/dL, group III - Lp(a)≥50 mg/dL (table). Results: Coronary heart disease, carotid artery disease, lower extremity artery disease, myocardial infarction and ischemic stroke were diagnosed in 61%; 34%; 23%; 42% and 11% patients, respectively. Lower extremity artery disease, carotid artery disease and myocardial infarction were more frequent in patients with Lp(a) concentration from 30 to 50 mg/dL compared to patients with Lp(a) <30 mg/dL: 36%, 41%, 48% vs. 17%, 30%, 36% respectively, p<0.01 for all. Subjects with Lp(a) 30-50 mg/dL (n=182, 15%) had a greater odds ratio of lower extremity artery disease, carotid artery disease and myocardial infarction compared to patients with Lp(a) <30 mg/dL (table). ROC analysis demonstrated that Lp(a) cut-off levels for lower extremity artery disease, carotid artery disease, coronary heart disease and myocardial infarction were 26; 21; 37 and 36 mg/dL, respectively. Conclusions: Our results demonstrate that in case of Lp(a) cut-off level of 50 mg/dL about 15% of patients are underestimated for the risk of ASCVD. Lp(a) cut-off level for ASCVD is between 20 and 40 mg/dL regarding the atherosclerosis location.

Download Full-text

Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease.

Clinical Chemistry ◽

10.1093/clinchem/32.5.778 ◽

1986 ◽

Vol 32 (5) ◽

pp. 778-781 ◽

Cited By ~ 115

Author(s):

H J Lenzen ◽

G Assmann ◽

R Buchwalsky ◽

H Schulte

Keyword(s):

Myocardial Infarction ◽

Coronary Heart Disease ◽

Heart Disease ◽

Apolipoprotein E ◽

Ldl Cholesterol ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Apolipoprotein E Polymorphism ◽

Artery Disease

Abstract We determined the frequencies of genetic apolipoprotein E isoforms in 570 survivors of myocardial infarction, all with demonstrable coronary heart disease, as compared with 624 healthy persons. In controls, E-4/E-3 heterozygosity was associated with total cholesterol concentrations of 1985 (SD 364) mg/L and low-density lipoprotein (LDL)-cholesterol concentrations of 1306 (SD 332) mg/L. Significantly lower values, 1811 (SD 312) mg/L and 1121 (SD 274) mg/L, respectively, were observed for E-3/E-2 heterozygous persons. In survivors of myocardial infarction, the respective values were significantly higher than in controls, differing between E-4/E-3 and E-3/E-2 heterozygous patients by 233 and 220 mg/L, respectively. Moreover, E-4/E-3 heterozygosity was accompanied by earlier age of myocardial infarction (48.8 +/- 7.4 years) as compared with E-3/E-2 heterozygosity (53.4 +/- 6.9 years) and E-3/E-3 homozygosity (51.2 +/- 7.7 years). Evidently, apolipoprotein E polymorphism can contribute to total and LDL-cholesterol concentrations in serum, thereby affecting risk of coronary heart disease and myocardial infarction.

Download Full-text

Drug Treatment in the Prevention of Coronary Artery Disease

10.1055/s-0039-1684684 ◽

1979 ◽

Author(s):

J.R.A. Mitchell

Keyword(s):

Coronary Artery Disease ◽

Coronary Heart Disease ◽

Clinical Trials ◽

Heart Disease ◽

Major Part ◽

Large Scale ◽

End Points ◽

Pump Failure ◽

Artery Disease

The disappointing performance of anticoagulants in the prophylaxis of coronary heart disease led to the realisation that components other than fibrin play a major part in the structure of arterial thrombi. Attention has therefore been focussed on the possible role of agents which modify platelet behaviour. Novel agents which alter thromboxane synthesis will not be available for large-scale clinical trials for some years, so the present trials are assessing the value of platelet-modifying agents which are already in use for other purposes. The implications of the Antura-Reinfarction study and the role of aspirin and persantin will be discussed.Attention will also be drawn to the importance of using valid end-points to assess potential anti-thrombotic regimes in coronary disease. The differential implications of using infarction, sudden death, pump failure, dysrhythmias and re-infarction as end-points in trials will be described.

Download Full-text

The Role of Traditional Chinese Medicine in the Regulation of Oxidative Stress in Treating Coronary Heart Disease

Oxidative Medicine and Cellular Longevity ◽

10.1155/2019/3231424 ◽

2019 ◽

Vol 2019 ◽

pp. 1-13 ◽

Cited By ~ 15

Author(s):

Xinyu Yang ◽

Tianmai He ◽

Songjie Han ◽

Xiaoyu Zhang ◽

Yang Sun ◽

...

Keyword(s):

Oxidative Stress ◽

Coronary Heart Disease ◽

Heart Disease ◽

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Antioxidant Treatment ◽

Molecular Systems ◽

Artery Disease ◽

Signal Activation

Oxidative stress has been closely related with coronary artery disease. In coronary heart disease (CHD), an excess of reactive oxygen species (ROS) production generates endothelial cell and smooth muscle functional disorders, leading to a disequilibrium between the antioxidant capacity and prooxidants. ROS also leads to inflammatory signal activation and mitochondria-mediated apoptosis, which can promote and increase the occurrence and development of CHD. There are several kinds of antioxidative and small molecular systems of antioxidants, such as β-carotene, ascorbic acid, α-tocopherol, and reduced glutathione (GSH). Studies have shown that antioxidant treatment was effective and decreased the risk of CHD, but the effect of the treatment varies greatly. Traditional Chinese medicine (TCM) has been utilized for thousands of years in China and is becoming increasingly popular all over the world, especially for the treatments of cardiovascular diseases. This review will concentrate on the evidence of the action mechanism of TCM in preventing CHD by modulating oxidative stress-related signaling pathways.

Download Full-text

Comparative Study between Diabetic and non- Diabetic Patients Regarding Prevalence of Coronary Artery Disease and Plaque Composition by Multi-detector CT Coronary Angiography

QJM ◽

10.1093/qjmed/hcaa068.015 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

H A Morsy ◽

L A Habib ◽

E H Abdeldayem ◽

A I Sayed

Keyword(s):

Myocardial Infarction ◽

Coronary Artery Disease ◽

Coronary Heart Disease ◽

Heart Disease ◽

Coronary Artery ◽

Diabetic Group ◽

Diabetic Patients ◽

Increased Risk ◽

Artery Disease ◽

Msct Angiography

Abstract Diabetes is known to be a major cardiovascular risk factor associated with significantly increased morbidity and mortality and particularly increased risk of major cardiac events especially myocardial infarction as a manifestation of highly incident coronary artery disease (CAD).This can lead to decreased life expectation and life quality. Major cause for myocardial infarction is plaque rupture. Prevalence of obstructive and non-obstructive plaques is increased in diabetic patients. Background and Objectives The prevalence of coronary heart disease in diabetic patients compared to non- diabetics and evaluating the composition of the plaque in diseased individuals in both groups by usage of multislice computed tomography (MSCT) angiography . Subjects and Methods A total of 80 consecutive MSCT angiography examinations were performed between August 2017 and June 2018. Of these, the patients were evaluated for the presence and type of atherosclerotic plaque and severity of luminal narrowing. Results Eighty (40 in the diabetic group and 40 in the non-diabetic group) patients underwent MSCT angiography with DM prevalence of 0.212 (95% Cl for AOR 0.056 -1.896). Among them, 20 patients (50 %) in the diabetic group and 14 patients (35 %) in the non-diabetic group had +ve coronary heart disease, 33.3 % had significant and moderately significant coronary narrowing on diabetic group and 31.3 % in non-diabetic group on MSCT angiography. Diabetic patients had more soft plaque compared with non-diabetic patients. Conclusion DM is not an independent factor for the disease occurrence in coronary artery disease but is a dependent factor in the association of other risk factors such as smoking ,hypertension and dyslipidemia.

Download Full-text